BRTX
BioRestorative Therapies, Inc.
Price Chart
Latest Quote
$0.40
+0.05 (+13.14%)
Current Price
| Previous Close | $0.35 |
| Open | $0.36 |
| Day High | $0.42 |
| Day Low | $0.35 |
| Volume | 845,985 |
Stock Information
| Shares Outstanding | 25.48M |
| Cash Equivalents | $3.59M |
| Revenue | $358K |
| Net Income | $-11.06M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $10.44M |
| EPS (TTM) | $-1.06 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $5.40M |
| Sales | $358K |
| Income | $-11.06M |
| Book/sh | $0.12 |
| Cash/sh | $0.14 |
| Employees | 13 |
Financial Ratios
| Quick Ratio | 2.23 |
| Current Ratio | 2.35 |
Returns & Margins
| ROA | -118.81% |
| ROE | -241.14% |
| Gross Margin | 92.09% |
| Operating Margin | -14612.57% |
Ownership
| Insider Ownership | 12.13% |
| Institutional Ownership | 7.26% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.79 |
| P/S | 29.16 |
| P/B | 3.44 |
Analyst Data
| Recommendation | none |
| Target Price | $8.00 |
Technical Indicators
| SMA20 | $0.37 |
| SMA50 | $0.28 |
| SMA200 | $0.85 |
| RSI | 42.77 |
| ATR | 0.0553 |
| Shares Float | 24.18M |
| Short Float | 26.25% |
| Short Ratio | 0.24 |
| Rel Volume | 0.02 |
Performance History
| Week | +8.94% |
| Month | +123.09% |
| Quarter | +59.88% |
| 6 Months | -62.07% |
| YTD | -66.43% |
| Year | -76.19% |
| 3 Years | -92.30% |
| 5 Years | -98.72% |
| 10 Years | -100.00% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $0.41 | 584,209 |
| 2026-06-17 | $0.40 | 848,300 |
| 2026-06-16 | $0.35 | 778,200 |
| 2026-06-15 | $0.39 | 1,256,500 |
| 2026-06-12 | $0.35 | 752,200 |
| 2026-06-11 | $0.38 | 439,200 |
| 2026-06-10 | $0.38 | 544,100 |
| 2026-06-09 | $0.39 | 1,025,900 |
| 2026-06-08 | $0.36 | 1,171,000 |
| 2026-06-05 | $0.41 | 1,366,000 |
| 2026-06-04 | $0.41 | 2,947,100 |
| 2026-06-03 | $0.34 | 1,574,600 |
| 2026-06-02 | $0.35 | 4,684,400 |
| 2026-06-01 | $0.41 | 5,296,200 |
| 2026-05-29 | $0.48 | 18,151,500 |
| 2026-05-28 | $0.48 | 28,096,700 |
| 2026-05-27 | $0.43 | 514,089,800 |
| 2026-05-26 | $0.25 | 10,708,800 |
| 2026-05-22 | $0.21 | 1,598,800 |
| 2026-05-21 | $0.19 | 1,514,400 |
| 2026-05-20 | $0.17 | 17,597,500 |
| 2026-05-19 | $0.18 | 393,200 |
About BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. The company develops programs related to the treatment of disc/spine disease and metabolic disorders. Its products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, as well as used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure; and ThermoStem, a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. The company also operates a commercial biocosmeceutical platform. In addition, it provides investigational curved needle device to deliver cells and/or other therapeutic products or material to the spine and discs, and other parts of the body. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. is headquartered in Melville, New York.
đ° Latest News
Sector Update: Healthcare Stocks Decline Tuesday Afternoon
MT Newswires âĸ 2026-05-26T17:50:29ZWhat Makes Biorestorative Therapies (BRTX) a New Buy Stock
Zacks âĸ 2026-05-15T16:00:02Z
Biorestorative Therapies, Inc. (BRTX) Reports Q1 Loss, Misses Revenue Estimates
Zacks âĸ 2026-05-14T23:40:02Z
Coherus Oncology (CHRS) Reports Q1 Loss, Lags Revenue Estimates
Zacks âĸ 2026-05-11T22:05:03Z
PTC Therapeutics (PTCT) Reports Q1 Loss, Tops Revenue Estimates
Zacks âĸ 2026-05-07T21:55:08Z
Geron (GERN) Reports Q1 Loss, Beats Revenue Estimates
Zacks âĸ 2026-05-06T12:25:04Z
Here's Why Biorestorative Therapies (BRTX) Looks Ripe for Bottom Fishing
Zacks âĸ 2026-04-27T13:55:01Z
Biorestorative Therapies, Inc. (BRTX) Reports Q4 Loss, Lags Revenue Estimates
Zacks âĸ 2026-03-26T22:25:02Z
Absci Corporation (ABSI) Reports Q4 Loss, Misses Revenue Estimates
Zacks âĸ 2026-03-24T21:25:01Z
Eton Pharmaceuticals, Inc. (ETON) Q4 Earnings Lag Estimates
Zacks âĸ 2026-03-19T21:30:01Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $23,844 | $28,072 | $0 | - |
| Cost Of Revenue | $23,844 | $28,072 | $0 | - |
| Total Revenue | $359,700 | $401,000 | $145,800 | $119,800 |
| Operating Revenue | $359,700 | $401,000 | $145,800 | $119,800 |
| Expenses | ||||
| Total Expenses | $16,006,832 | $11,956,194 | $15,283,241 | $18,983,307 |
| Other Income Expense | $1,138,950 | $1,959,736 | $4,167,444 | $5,629,561 |
| Other Non Operating Income Expenses | $17,448 | $150,850 | $169,664 | $107,088 |
| Net Non Operating Interest Income Expense | $266,207 | $616,077 | $552,293 | $11,650 |
| Operating Expense | $15,982,988 | $11,928,122 | $15,283,241 | $18,983,307 |
| General And Administrative Expense | $5,888,317 | $5,221,209 | $11,331,983 | $15,580,473 |
| Other Operating Expenses | - | - | $-83,333 | $-110,518 |
| Total Other Finance Cost | - | - | - | $-11,650 |
| Interest Expense | - | - | - | - |
| Interest Expense Non Operating | - | - | - | - |
| Selling And Marketing Expense | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-14,241,975 | $-8,979,381 | $-10,417,704 | $-13,222,296 |
| Net Interest Income | $266,207 | $616,077 | $552,293 | $11,650 |
| Interest Income | $266,207 | $616,077 | $552,293 | $11,650 |
| Normalized Income | $-15,363,477 | $-10,788,267 | $-14,415,484 | $-18,744,769 |
| Net Income From Continuing And Discontinued Operation | $-14,241,975 | $-8,979,381 | $-10,417,704 | $-13,222,296 |
| Total Operating Income As Reported | $-15,647,132 | $-11,555,194 | $-15,220,774 | $-18,974,025 |
| Net Income Common Stockholders | $-14,241,975 | $-8,979,381 | $-10,417,704 | $-13,222,296 |
| Net Income | $-14,241,975 | $-8,979,381 | $-10,417,704 | $-13,222,296 |
| Net Income Including Noncontrolling Interests | $-14,241,975 | $-8,979,381 | $-10,417,704 | $-13,222,296 |
| Net Income Continuous Operations | $-14,241,975 | $-8,979,381 | $-10,417,704 | $-13,222,296 |
| Pretax Income | $-14,241,975 | $-8,979,381 | $-10,417,704 | $-13,222,296 |
| Interest Income Non Operating | $266,207 | $616,077 | $552,293 | $11,650 |
| Operating Income | $-15,647,132 | $-11,555,194 | $-15,137,441 | $-18,863,507 |
| Gross Profit | $335,856 | $372,928 | $145,800 | - |
| Special Income Charges | - | - | $0 | $250,000 |
| Per Share | ||||
| Diluted EPS | $-1.58 | $-1.16 | $-2.47 | $-3.65 |
| Basic EPS | $-1.58 | $-1.16 | $-2.47 | $-3.65 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-16,558,649 | $-13,175,024 | $-18,969,486 | $-24,265,435 |
| Total Unusual Items | $1,121,502 | $1,808,886 | $3,997,780 | $5,522,473 |
| Total Unusual Items Excluding Goodwill | $1,121,502 | $1,808,886 | $3,997,780 | $5,522,473 |
| Reconciled Depreciation | $209,985 | $189,056 | $165,735 | $120,545 |
| EBITDA (Bullshit earnings) | $-15,437,147 | $-11,366,138 | $-14,971,706 | $-18,742,962 |
| EBIT | $-15,647,132 | $-11,555,194 | $-15,137,441 | $-18,863,507 |
| Diluted Average Shares | $8,993,115 | $7,763,932 | $4,218,347 | $3,617,858 |
| Basic Average Shares | $8,993,115 | $7,763,932 | $4,218,347 | $3,617,858 |
| Diluted NI Availto Com Stockholders | $-14,241,975 | $-8,979,381 | $-10,417,704 | $-13,222,296 |
| Gain On Sale Of Security | $1,121,502 | $1,808,886 | $3,997,780 | $5,272,473 |
| Research And Development | $10,094,671 | $6,706,913 | $4,034,591 | $3,513,352 |
| Selling General And Administration | $5,888,317 | $5,221,209 | $11,331,983 | $15,580,473 |
| Other Gand A | $5,888,317 | $5,221,209 | $11,331,983 | $15,580,473 |
| Other Special Charges | - | - | - | $-250,000 |
| Restructuring And Mergern Acquisition | - | - | - | - |
Fetched: 2026-06-18
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-177,454 | $7,907,448 | $9,290,683 | $9,486,901 |
| Total Assets | $4,079,635 | $12,279,799 | $12,611,720 | $16,434,691 |
| Total Non Current Assets | $942,773 | $1,135,578 | $1,221,194 | $1,306,201 |
| Non Current Deferred Assets | $49,808 | $148,697 | $0 | - |
| Goodwill And Other Intangible Assets | $534,198 | $623,945 | $713,692 | $803,438 |
| Other Intangible Assets | $534,198 | $623,945 | $713,692 | $803,438 |
| Current Assets | $3,136,862 | $11,144,221 | $11,390,526 | $15,128,490 |
| Other Current Assets | $168,440 | $223,230 | $305,231 | $363,082 |
| Receivables | $15,500 | $188,400 | $19,300 | $16,000 |
| Accounts Receivable | $15,500 | $188,400 | $19,300 | $16,000 |
| Cash Cash Equivalents And Short Term Investments | $2,952,922 | $10,732,591 | $11,065,995 | $14,749,408 |
| Cash And Cash Equivalents | $1,511,188 | $547,890 | $884,377 | $1,713,772 |
| Prepaid Assets | - | - | - | - |
| Cash Financial | - | - | - | - |
| Debt | ||||
| Total Debt | - | $0 | $162,317 | $301,645 |
| Current Debt And Capital Lease Obligation | - | - | $162,317 | $139,328 |
| Long Term Debt And Capital Lease Obligation | - | - | - | $162,317 |
| Long Term Debt | - | - | - | - |
| Current Debt | - | - | - | - |
| Other Current Borrowings | - | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $3,722,891 | $3,748,406 | $2,607,345 | $6,144,352 |
| Total Non Current Liabilities Net Minority Interest | $0 | $0 | $0 | $162,317 |
| Current Liabilities | $3,722,891 | $3,748,406 | $2,607,345 | $5,982,035 |
| Other Current Liabilities | $1,399,349 | $2,520,851 | $1,543,953 | $5,541,733 |
| Payables And Accrued Expenses | $1,610,042 | $523,555 | $901,075 | $300,974 |
| Payables | $1,484,568 | $508,555 | $189,389 | $170,902 |
| Other Payable | $143,073 | $25,485 | - | - |
| Accounts Payable | $1,341,495 | $483,070 | $189,389 | $170,902 |
| Equity | ||||
| Common Stock Equity | $342,762 | $8,517,411 | $9,990,393 | $10,275,157 |
| Preferred Stock Equity | $13,982 | $13,982 | $13,982 | $15,182 |
| Total Equity Gross Minority Interest | $356,744 | $8,531,393 | $10,004,375 | $10,290,339 |
| Stockholders Equity | $356,744 | $8,531,393 | $10,004,375 | $10,290,339 |
| Retained Earnings | $-169,920,690 | $-155,678,715 | $-146,699,334 | $-136,281,630 |
| Other | ||||
| Preferred Shares Number | $1,398,158 | $1,543,158 | $1,398,158 | $1,518,158 |
| Ordinary Shares Number | $8,876,242 | $6,919,919 | $4,706,917 | $3,677,775 |
| Share Issued | $8,876,242 | $6,919,919 | $4,706,917 | $3,677,775 |
| Tangible Book Value | $-191,436 | $7,893,466 | $9,276,701 | $9,471,719 |
| Invested Capital | $342,762 | $8,517,411 | $9,990,393 | $10,275,157 |
| Working Capital | $-586,029 | $7,395,815 | $8,783,181 | $9,146,455 |
| Total Capitalization | $356,744 | $8,531,393 | $10,004,375 | $10,290,339 |
| Additional Paid In Capital | $170,262,565 | $164,195,434 | $156,689,256 | $146,556,418 |
| Capital Stock | $14,869 | $14,674 | $14,453 | $15,551 |
| Common Stock | $887 | $692 | $471 | $369 |
| Preferred Stock | $13,982 | $13,982 | $13,982 | $15,182 |
| Pensionand Other Post Retirement Benefit Plans Current | $713,500 | $704,000 | - | - |
| Current Accrued Expenses | $125,474 | $15,000 | $711,686 | $130,072 |
| Net PPE | $358,767 | $362,936 | $507,502 | $502,763 |
| Accumulated Depreciation | $-1,231,374 | $-1,111,136 | $-1,011,828 | $-935,839 |
| Gross PPE | $1,590,141 | $1,474,072 | $1,519,330 | $1,438,602 |
| Leases | $342,048 | $342,048 | $342,048 | $342,048 |
| Construction In Progress | $64,128 | $0 | - | - |
| Other Properties | $905,495 | $853,554 | $898,812 | $594,985 |
| Machinery Furniture Equipment | $278,470 | $278,470 | $278,470 | $259,809 |
| Other Short Term Investments | $1,441,734 | $10,184,701 | $10,181,618 | $13,035,636 |
| Capital Lease Obligations | - | $0 | $162,317 | $301,645 |
| Current Capital Lease Obligation | - | $0 | $162,317 | $139,328 |
| Long Term Capital Lease Obligation | - | - | $0 | $162,317 |
| Buildings And Improvements | - | - | $151,447 | $241,760 |
Fetched: 2026-06-18
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-10,905,032 | $-8,336,535 | $-6,601,254 | $-6,353,323 |
| Operating Activities | ||||
| Operating Cash Flow | $-10,788,963 | $-8,230,346 | $-6,430,211 | $-5,913,100 |
| Cash Flow From Continuing Operating Activities | $-10,788,963 | $-8,230,346 | $-6,430,211 | $-5,913,100 |
| Operating Gains Losses | $-1,392,075 | $-2,432,687 | $-4,566,848 | $-5,348,477 |
| Investing Activities | ||||
| Capital Expenditure | $-116,069 | $-106,189 | $-171,043 | $-440,223 |
| Investing Cash Flow | $8,897,470 | $514,529 | $3,252,043 | $-13,399,855 |
| Cash Flow From Continuing Investing Activities | $8,897,470 | $514,529 | $3,252,043 | $-13,399,855 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $3,096,250 | $0 | $2,348,773 | $0 |
| Financing Cash Flow | $2,854,791 | $7,379,330 | $2,348,773 | $0 |
| Cash Flow From Continuing Financing Activities | $2,854,791 | $7,379,330 | $2,348,773 | $0 |
| Net Other Financing Charges | $-282,624 | $-148,697 | - | - |
| Net Common Stock Issuance | $3,096,250 | $0 | $2,348,773 | $0 |
| Common Stock Issuance | $3,096,250 | $0 | $2,348,773 | $0 |
| Other | ||||
| Interest Paid Supplemental Data | $0 | $0 | $0 | $0 |
| Income Tax Paid Supplemental Data | $0 | $0 | $0 | $0 |
| End Cash Position | $1,511,188 | $547,890 | $884,377 | $1,713,772 |
| Beginning Cash Position | $547,890 | $884,377 | $1,713,772 | $21,026,727 |
| Changes In Cash | $963,298 | $-336,487 | $-829,395 | $-19,312,955 |
| Proceeds From Stock Option Exercised | $41,165 | $7,528,027 | $0 | - |
| Net Investment Purchase And Sale | $9,013,539 | $620,718 | $3,423,086 | $-12,959,632 |
| Sale Of Investment | $11,692,686 | $21,508,641 | $20,964,373 | $9,492,304 |
| Purchase Of Investment | $-2,679,147 | $-20,887,923 | $-17,541,287 | $-22,451,936 |
| Net PPE Purchase And Sale | $-116,069 | $-106,189 | $-171,043 | $-265,223 |
| Purchase Of PPE | $-116,069 | $-106,189 | $-171,043 | $-265,223 |
| Change In Working Capital | $1,309,476 | $28,653 | $515,326 | $14,144 |
| Change In Other Current Liabilities | $0 | $-162,317 | $-139,328 | $-163,132 |
| Change In Payables And Accrued Expense | $1,034,806 | $326,479 | $600,103 | $115,177 |
| Change In Accrued Expense | $195,281 | $32,799 | $581,616 | $-4,898 |
| Change In Payable | $839,525 | $293,680 | $18,487 | $120,075 |
| Change In Account Payable | $839,525 | $293,680 | $18,487 | $120,075 |
| Change In Prepaid Assets | $101,770 | $33,591 | $57,851 | $73,099 |
| Change In Receivables | $172,900 | $-169,100 | $-3,300 | $-11,000 |
| Changes In Account Receivables | $172,900 | $-169,100 | $-3,300 | $-11,000 |
| Stock Based Compensation | $3,325,626 | $2,812,566 | $7,782,967 | $12,612,862 |
| Depreciation Amortization Depletion | $209,985 | $189,056 | $165,735 | $120,545 |
| Depreciation And Amortization | $209,985 | $189,056 | $165,735 | $120,545 |
| Amortization Cash Flow | $89,747 | $89,747 | $89,746 | $78,332 |
| Amortization Of Intangibles | $89,747 | $89,747 | $89,746 | $78,332 |
| Depreciation | $120,238 | $99,309 | $75,989 | $42,212 |
| Gain Loss On Investment Securities | $-1,392,075 | $-2,432,687 | $-4,566,848 | $-5,348,477 |
| Net Income From Continuing Operations | $-14,241,975 | $-8,979,381 | $-10,417,704 | $-13,222,296 |
| Other Non Cash Items | - | $151,447 | $90,313 | $-89,878 |
| Net Intangibles Purchase And Sale | - | - | $0 | $-175,000 |
| Purchase Of Intangibles | - | - | $0 | $-175,000 |
| Issuance Of Debt | - | - | - | $0 |
| Net Issuance Payments Of Debt | - | - | - | $0 |
| Net Long Term Debt Issuance | - | - | - | $0 |
| Long Term Debt Issuance | - | - | - | $0 |
| Unrealized Gain Loss On Investment Securities | - | - | - | $-33,665 |
| Change In Interest Payable | - | - | - | - |
Fetched: 2026-06-18